Management of Complications of BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review

被引：0
|
作者：
Khanam, Razwana [1 ]
Batool, Saba [2 ]
Najmuddin, Mohammed Musa [3 ]
Usman, Rana [4 ]
Kuriakose, Kiran [5 ]
Ahmed, Arooj [6 ]
Rehman, Mohammad Ebad Ur [7 ]
Roksana, Zinath [8 ]
Anwer, Faiz [9 ]
机构：
[1] Baystate Med Ctr, Springfield, MA USA
[2] Unity Point Methodist Hosp, Peoria, IL USA
[3] Wright Ctr Grad Med Educ, Scranton, PA USA
[4] Univ Tennessee, Hlth Ctr, Memphis, TN USA
[5] UPMC Mercy, Pittsburgh, PA USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Rawalpindi Med Univ, Rawalpindi, Pakistan
[8] Feni Sadar Hosp, Feni, Bangladesh
[9] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-164871
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12494 / 12495
页数：2
相关论文
共 50 条
  • [31] Real world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma
    Midha, Shonali
    Leblebjian, Houry
    Laubach, Jacob
    Mo, Clifton
    Sperling, Adam
    Nadeem, Omar
    Bianchi, Giada
    Hartley-Brown, Monique
    Ramsdell, Linda
    Donadio, Kristen
    Chun, Emerald
    Belanger, Megan
    Dobrusin, Irina
    Ghobrial, Irene
    Richardson, Paul
    Anderson, Kenneth
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S53 - S53
  • [32] Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
    Rees, Matthew J.
    Mammadzadeh, Aytaj
    Bolarinwa, Abiola
    Elhaj, Mohammed E.
    Bohra, Arwa
    Bansal, Radhika
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Chhabra, Saurabh
    Khot, Amit
    Hayman, Suzanne
    Dispenzieri, Angela
    Buadi, Francis
    Dingli, David
    Warsame, Rahma
    Kapoor, Prashant
    Gertz, Morie A.
    Muchtar, Eli
    Kourelis, Taxiarchis
    Gonsalves, Wilson
    Rajkumar, S. Vincent
    Lin, Yi
    Kumar, Shaji
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [33] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
    Anderson, Larry D., Jr.
    Munshi, Nikhil C.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
    Al Hadidi, Samer
    Szabo, Aniko
    Esselmann, Jean
    Hammons, Lindsay
    Hussain, Munawwar
    Ogunsesan, Yetunde
    Thalambedu, Nishanth
    Khan, Fatima
    Sethi, Jaskirat
    Janardan, Abhishek
    Radhakrishnan, Sabarinath
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Dhakal, Binod
    Janz, Siegfried
    Chhabra, Saurabh
    D'Souza, Anita
    Zangari, Maurizio
    van Rhee, Frits
    Mohan, Meera
    BLOOD, 2022, 140 : 8038 - 8039
  • [35] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
    Rejeski, Kai
    Hansen, Doris K.
    Bansal, Radhika
    Sesques, Pierre
    Ailawadhi, Sikander
    Logue, Jennifer M.
    Braeunlein, Eva
    dos Santos, David M. Cordas M.
    Freeman, Ciara L.
    Alsina, Melissa
    Theurich, Sebastian
    Wang, Yucai
    Krackhardt, Angela M.
    Locke, Frederick L.
    Bachy, Emmanuel
    Jain, Michael D.
    Lin, Yi
    Subklewe, Marion
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [36] BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model
    Comstock, Melissa L.
    O'Steen, Shyril
    Lin, Yukang
    Hamlin, Donald
    Wilbur, D. Scott
    Orozco, Johnnie J.
    Storb, Rainer F.
    Walter, Roland B.
    Atilla, Pinar Ataca
    Till, Brian G.
    Hill, Geoffrey R.
    Sandmaier, Brenda M.
    Green, Damian J.
    BLOOD, 2023, 142
  • [37] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
    Kai Rejeski
    Doris K. Hansen
    Radhika Bansal
    Pierre Sesques
    Sikander Ailawadhi
    Jennifer M. Logue
    Eva Bräunlein
    David M. Cordas dos Santos
    Ciara L. Freeman
    Melissa Alsina
    Sebastian Theurich
    Yucai Wang
    Angela M. Krackhardt
    Frederick L. Locke
    Emmanuel Bachy
    Michael D. Jain
    Yi Lin
    Marion Subklewe
    Journal of Hematology & Oncology, 16
  • [38] Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
    Kambhampati, Swetha
    Sheng, Ying
    Huang, Chiung-Yu
    Bylsma, Sophia
    Lo, Mimi
    Kennedy, Vanessa
    Natsuhara, Kelsey
    Martin, Thomas
    Wolf, Jeffrey
    Shah, Nina
    Wong, Sandy W.
    BLOOD ADVANCES, 2022, 6 (07) : 2045 - 2054
  • [39] The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
    Rejeski, Kai
    Hansen, Doris K.
    Bansal, Radhika
    Sesques, Pierre
    Ailawadhi, Sikander
    Logue, Jennifer M.
    Freeman, Ciara L.
    Alsina, Melissa
    Theurich, Sebastian
    Locke, Frederick L.
    Bachy, Emmanuel
    Jain, Michael D.
    Lin, Yi
    Subklewe, Marion
    BLOOD, 2022, 140 : 7506 - 7508
  • [40] Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
    Hu, Hongxiang
    Li, Yan
    Piasecki, Julia
    Hosseyni, Daniela
    Yan, Zhicheng
    Liu, Xianghong
    Ogasawara, Ken
    Zhou, Simon
    Cheng, Yiming
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1163 - 1171
12345